Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Calcifediol”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources

Calcifediol antagonizes PTH action on water and phosphate absorption in rabbit pars recta.

Reports of the effects of calcifediol (25-hydroxycholecalciferol) on phosphate excretion, alone or with parathyroid hormone (PTH), or with adenosine 3',5'-cyclic monophosphate (cAMP), have been conflicting. The purpose of this investigation was to examine the effects on fluid and phosphate transport by the rabbit pars recta of calcifediol alone or with PTH. In tubule segments obtained from rabbits fed a normal diet, the addition of 10 or 30 nM calcifediol to the bath did not alter fluid absorption (Jv) or lumen-to-bath phosphate flux (JPil----b). However, pharmacological concentrations did inhibit Jv by 20.9 +/- 5.6% (100 nM, P less than 0.02) and 37.9 +/- 9.4% (1.0 microM, P less than 0.01) and JPil----b by 18.5 +/- 6.6% (100 nM, P less than 0.05) and 40.5 +/- 8.6% (1.0 microM, P less than 0.01). In the presence of 30 nM, 100 nM, or 1.0 microM calcifediol, neither 0.25 nor 1.0 U/ml PTH inhibited JPil----b. A modest decline in Jv did occur with 1.0 U/ml PTH in the presence of 30 nM and 100 nM calcifediol. Unlike calcifediol, when 10 nM calcitriol (1,25-dihydroxycholecalciferol) was present in the bath, 0.2 U/ml PTH significantly depressed Jv and JPil----b. To investigate the mechanism of action of high calcifediol concentration, measurement of the collected minus perfused tubule fluid chloride concentration difference was performed.(ABSTRACT TRUNCATED AT 250 WORDS)

Absorption↗

Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis.

Mineral metabolism was studied in 31 patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) for a year. After baseline observations, 1-year calcifediol treatment was started in all the patients (100 micrograms/day). After therapy, progressive normalization of calcium levels was found in all the patients, while plasma phosphate did not change. After therapy, plasma alkaline phosphatase and parathyroid hormone decreased significantly. 1,25-Dihydroxyvitamin D showed a slight increase, and 25-hydroxyvitamin D (extremely low at the start of the study) rose, reaching normal levels, after 1 year of treatment. Bone mineral density and bone biopsy indexes showed general improvement after calcifediol. In conclusion, calcifediol seems to act positively on the disorders of mineral metabolism in CAPD.

Alkaline Phosphatase↗

The effects of calciferol and its metabolites on patients with chronic renal failure. I. Calciferol, dihydrotachysterol, and calcifediol.

The available data with regard to the use of calciferol, dihydrotachysterol, and calcifediol in the management of renal insufficiency are reviewed. Very limited data are available with regard to calciferol therapy; with the advent of more active metabolites, the use of calciferol is not warranted. Dihydrotachysterol seems to be effective in the treatment of renal patients with osteitis fibrosa; its low cost makes therapy with this compound a reasonable alternative, although it should not be used in the treatment of patients with liver disease. Calcifediol seems to be effective in patients with osteitis fibrosa; however, limited data on histologic characteristics of bone are available. Detailed prospective studies are necessary to establish the therapeutic benefit of calcifediol.

Absorption↗

[Calcifediol and calcitonin in the therapy of rheumatoid arthritis. A short-term controlled study].

A short-term study (30 days) has been carried out on 45 patients suffering from rheumatoid arthritis with radiologically verified osteoporosis and definite pain symptomatology. The patients were divided at random into three groups (A, B, C) of 15 each. Group A was given basic therapy (calcium, dichlrophenac, nor-androstenolone) with addition of calcifediol. Group B received basic therapy plus calcitonine in paraphysiological doses. Group C was treated with basic therapy only (highly effective on its own). Observation and treatment were brief but able to provide useful indications regarding the implementation of longer courses of treatment (3-6 months). At the end of treatment, results were submitted to biometric control. With the aid of statistics it can thus be stated that alkaline phosphatase and hydroxyprolinuria fall in group B (basic treatment + calcitonine) and this suggests that the treatment causes some improvement in the exchangeable bone calcium pool. The values of these parameters also fall with the addition of calcifediol to basic therapy, but this fall is not very high. Pain symptomatology is also favourably affected, and to a statistically significant extent, by the three treatments: group A patients (basic + calcifediol) show greater improvement compared with straightforward basic therapy, but the best results are encountered in group B, treated with an association of basic and calcitonine. No side-effects were observed.

Adult↗

Calcifediol in chronic renal insufficiency. Skeletal response.

Quantitative histology of thin, nondecalcified sections was performed on sequential bone biopsy specimens from five patients undergoing long-term hemodialysis and treated with calcifediol (25-hydroxycholecalciferol) for periods of three to nine months. With increase of intestinal absorption of calcium and decline of circulating immunoreactive parathyroid hormone and alkaline phosphatase, the bones of each patient exhibited striking histological improvement. The group as a whole showed statistically significant decreases in osteoclast number and in the percentages of osteoid surface covered by active osteoblasts. Marrow fibrosis was either eliminated or strikingly decreased in each patient. Osteoid volume significantly declined in four of five patients. In patients with osteitis fibrosa as the predominant histological lesion, calcifediol therapy resulted in decreased calcification front activity. Increased activity was the result when osteomalacia predominated.

Adult↗

[Does calcifediol replace vitamin D as a preventive and therapeutic agent?].

Cholecalciferol (CC) given orally is not utilized as efficiently as the CC produced by cutaneous UV light. The infant receives only minute amounts of CC by breast feeding, abolishing therefore the role of a vitamin for CC. The most important D-metabolite of human milk, the calcifediol (CF), however, has transient vitamin character. CF is both resorbed more efficiently by the intestine and it effects mineral metabolism faster via kidney than CC, which needs hydroxylation in the liver first. Thus CF shows advantages in prophylaxis and therapy. However, different (lower) dosages and the danger of hypercalcemia should be kept in mind using CF.

Breast Feeding↗

25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity.

A prospective study of renal osteodystrophy in moderate renal insufficiency was undertaken to assess the effects of 25(OH)D3 (Calcifediol) on healing of bone lesions and improvement of linear growth. One year after entering the study, the mean group growth velocity increased into the normal range and remained there in the next two therapy years. A significant correlation existed between pretherapy and one-year therapy values of growth velocity and serum 25(OH)D3 concentration. Qualitative bone histology obtained by transilial bone biopsy was also evaluated during the course of study. Catch-up growth was not seen, but potential for such growth may exist in later years in our patients.

Child↗

[Prevention of hypocalcemia in low-birth-weight newborn infants: a comparative clinical study on the efficacy of ergocalciferol (Vit. D2) and calcifediol (Vit. 25(OH)D3)].

During the first week of life, 400 IU per day of 25(OH)D3 were given to 126 preterm and 112 full-term, small for date newborn infants, while 1000 UI per day of Vitamin D2 were given to 18 preterm and 27 full-term, small for date newborn infants, in order to compare their effectiveness for the prevention of neonatal hypocalcemia. 67 preterm and 67 full-term newborns were included in the control group. The incidence of late hypocalcemia was reduced from 16.4% to 0 in full-term babies and from 6% to 2.4% in preterm babies by the 25(OH)D3 but not by Vit. D2 administration. The incidence of early hypocalcemia was not modified at all. The Authors suggest 25(OH)D3 administration to prevent the late hypocalcemia and, together with calcium support, to treat the early hypocalcemia in the low birth weight newborn.

Calcifediol↗

Plasma concentrations of 25-hydroxyvitamin-D3 (calcifediol) as an indicator of ultraviolet radiation.

Vitamin D3 is produced in the skin of animals and humans by the sun's ultraviolet rays (UVB region, 290-315 nm). The main metabolite 25-hydroxyvitamin-D3 has a seasonal variation, depending on the ultraviolet radiation. In the Antarctic preliminary investigations on penguins (Pygoscelis papua), female sea elephants (Mirounga leonina), and humans showed that there was an increase in plasma 25-hydroxyvitamin-D3 concentrations during UV-exposure in all three species. This metabolite can therefore be regarded as a molecular indicator of UV radiation. The possibility to use this compound in a long term monitoring program, for UV radiation, is under investigation.

Animals↗

Effect of disodium monofluorophosphate, calcium and vitamin D supplementation on bone mineral density in patients chronically treated with glucocorticosteroids: a prospective, randomized, double-blind study.

To study the effect of fluoride on bone mineral density (BMD) in patients treated chronically with glucocorticosteroids, 15 subjects (renal grafted, n = 12; skin disease, n = 1; broncho pulmonary disorder, n = 1; Crohn's disease, n = 1) were prospectively studied in a double-blinded manner and randomly allocated either to group 1 (n = 8) receiving 13.2 mg/day fluoride given as disodium monofluorophosphate (MFP) supplemented with calcium (1,000 mg/day) and 25-hydroxyvitamin D (calcifediol) (50 micrograms/day), or to group 2 (n = 7) receiving Cas+ calcifediol alone. An additional group of 14 renal transplant patients treated chronically with glucocorticosteroids but exempt of specific therapeutic intervention for bone disease was set up as historical controls. BMD was measured by dual-energy X-ray absorptiometry (DXA, Hologic QDR 1000) performed at months 0, 6 and 12 for groups 1 and 2 (lumbar spine, total upper femur, diaphysis and epiphysis of distal tibia), or 11-31 months apart with calculation of linear yearly changes for the historical cohort. Lumbar BMD tended to rise in groups 1 and 2, and to fall in group 3, the change reaching statistical significance (p < 0.05) in group 1, thus leading to a significant difference between groups 1 and 3 (p < 0.05). At upper femur, tibial diaphysis and tibial epiphysis, no significant change in BMD occurred in any of the groups. In conclusion, lumbar BMD rises more after a mild dosis of fluoride given as MFP and combined to calcium and calcifediol than on Ca+ calcifediol alone, without changes in BMD at the upper femur or distal tibia.

Absorptiometry, Photon↗

Calcitriol dosage in osteomalacia, hypoparathyroidism and attempted treatment of myositis ossificans progressiva.

Mineral retention was measured during 39 metabolic balance studies in 34 patients with nutritional osteomalacia or late rickets; they were divided into 5 treatment groups consisting of oral vitamin D, artificial ultra-violet irradiation, 25-hydroxycholecalciferol (calcifediol), 1 alpha-hydroxycholecalciferol (alfacalcidol) and 1 alpha, 25-hydroxycholecalciferol (calcitriol). With the 1 alpha-hydroxylated derivatives, initial dosage of 2 to 6 micrograms daily was required to achieve optimal healing rates by comparison with other responses. Mineral retention was markedly enhanced by supplementation with microcrystalline hydroxyapatite compound (MCHC); untreated X-linked hypophosphataemic rickets healed in 7 weeks on 10 micrograms alfacalcidol daily and 6 grams MCHC daily without developing hypercalcaemia. By contrast, adult-presenting hypophosphataemic osteomalacia developed early hypercalcaemia on the same treatment; additional phosphate supplementation, without changing other treatment, abolished hypercalcaemia and improved calcium retention. A long-term crossover trial of the vitamins D in 6 patients with hypoparathyroidism suggested that relative potencies were as follows (assigning to vitamin D an arbitrary potency of l): vitamin D2 (or D3) l: dihydrotachysterol (DHT) 3: calcifediol 10: alfacalcidol 750: calcitriol 1500. The two-fold superiority of calcitriol over alfacalcidol was evident. Calcifediol and vitamin D controlled plasma calcium at comparable levels of circulating 25-hydroxyvitamin D (25-OH-D), elevated 25-OH-D persisting at least 1 to 2 years after discontinuing long-term (greater than 4 years) vitamin D. In 2 patients with myositis ossificans progressiva treated with 10 to 20 micrograms calcitriol daily, hypercalcaemia was minimized by a low-calcium diet supplemented with cellulose phosphate, suggesting that bone resorption did not play a major role in vitamin D intoxication. Net mineral loss was documented in a young male patient but not in a menopausal female, suggesting that calcitriol treatment was not likely to produce post-menopausal osteoporosis.

Bone Resorption↗